Chinese Pharmaceutical Industry

Summary

China is expected to become the fifth largest drug market in the world by 2010. Growth will be driven by factors such as an increasingly ageing population, large market size (urban and rural), government support in restructuring the highly fragmented industry, IPR policies, as well as increasing life expectancy. China will remain an attractive location to foreign drug companies, because China offers many advantages in terms of the size of its marketplace, the relatively easy access to patients who are available for clinical trials, and lower clinical trial costs.

China has made considerable progress towards an improved standard of living for its population, including better health, reduced levels of poverty, and strong macroeconomic growth. The market for high quality, patient-oriented healthcare services is small, but growing steadily. Most Chinese lack health insurance and only a fraction of the population can afford top-end Western medical care. Currently, there are many successful foreign and joint venture healthcare service providers already in China. Their experiences point to growing opportunities for foreign companies looking to invest in this segment of the market.

Contents

INDUSTRY OVERVIEW

INDUSTRY GROWTH
PHARMACEUTICAL MARKET POTENTIAL
DRIVERS OF CHINESE PHARMACEUTICAL INDUSTRY
INDUSTRY CHARACTERISTICS
DOMESTIC INDUSTRY
DISEASE PROFILE
DRUGS WITH LARGEST MARKET SCOPE
PRODUCT STRATEGIES

KEY TRENDS

INDUSTRY CHALLENGES
IMPACT OF WTO MEMBERSHIP
INDUSTRY CONSOLIDATION
ROLE OF GOVERNMENT
IMPORTS VS. EXPORTS
INCENTIVE STRUCTURES

INDUSTRY IN TRANSITION

REGULATIONS
R&D INVESTMENTS
R&D EXTERNALISATION
MANUFACTURING
DISTRIBUTION
EXPORTS
COLLABORATION WITH MULTINATIONALS
ADVANTAGES FOR CHINESE ENTITIES
ADVANTAGES FOR MULTINATIONALS
MULTINATIONAL MANUFACTURING FACILITIES
INTERACTIONS WITH US FDA
CHALLENGES
FUTURE OUTLOOK POST-REFORM

GOVERNMENT POLICIES

PHARMACEUTICAL PRICING POLICY
DRUG PRICING REFORMS
PRICING OF DRUGS
PROFIT MARGINS
MARKET LIBERALISATION
REGULATORY FRAMEWORKS
INCENTIVES
RATIONALISATION OF MARKET
SFDA CLASSIFICATION

SOCIAL AND CULTURAL ISSUES

CHINESE BUSINESS NETWORKS
NEGOTIATION
THE POLITICAL SYSTEM
THE LEGAL SYSTEM
MACRO ECONOMIC ENVIRONMENT
TECHNOLOGICAL ENVIRONMENT

BIOTECHNOLOGY INDUSTRY

GOVERNMENT ROLE
RESEARCH INITIATIVES
CHALLENGES

CHINESE HEALTHCARE SYSTEM

KEY TRENDS IN HEALTHCARE
MAJOR DISEASES
DISEASE PREVENTION MECHANISMS
PAST EXPERIENCES
HEALTH CARE DELIVERY NETWORK
EVOLVING HEALTH CARE DELIVERY NETWORK
HEALTHCARE SYSTEM CHANGES
STRUCTURE OF CHINA’S HEALTHCARE SYSTEM
HEALTHCARE FINANCING
REGULATIONS
KEY PLAYERS IN THE CHINESE HEALTHCARE SYSTEM
HOSPITALS
STATE-OWNED HOSPITALS
HOSPITAL FUNDING
FOREIGN INVESTORS IN CHINESE HEALTHCARE
JOINT VENTURES
LESSONS FROM THE PAST
CHALLENGES FOR FOREIGN INVESTORS
POLICY RECOMMENDATIONS
RURAL HEALTHCARE
URBAN HEALTHCARE
HEALTHCARE PERSONNEL
GOVERNMENTAL PRIORITIES IN HEALTHCARE
HEALTHCARE REFORMS IN CHINA
HEALTHCARE POLICY RECOMMENDATIONS
HEALTHCARE FINANCING REFORMS
NATIONAL ESSENTIAL DRUG LIST (NEDL)
HEALTHCARE INSURANCE IN CHINA
CHARACTERISTICS
HEALTHCARE INSURANCE REFORMS

MEDICAL EQUIPMENTS AND DEVICES MARKET

TOP SELLING PRODUCT CATEGORIES
MARKET DYNAMICS
MULTINATIONAL PRESENCE
COMPETITION
KEY MARKET CHARACTERISTICS
OPPORTUNITIES TO EXPLOIT
MARKET REGULATORS AND THEIR ROLES
CHALLENGES
STRATEGIES FOR SUCCESS

CHINA’S MEDICAL INSURANCE MARKET

IMPACT OF WTO
INSURANCE REGULATIONS IN CHINA
LIBERALISATION OF INSURANCE INDUSTRY
DOMESTIC AND FOREIGN INSURANCE COMPANIES
RECOMMENDATIONS
POTENTIAL FOR INSURANCE MARKET IN CHINA
URBAN MEDICAL INSURANCE
RURAL MARKET FOR MEDICAL INSURANCE
INDUSTRY CHALLENGES
FUTURE DIRECTIONS

CHINA’S DRUG PRICING REFORM AND DRUG PRICING POLICY

CHALLENGES IN THE CHINESE DRUG PRICING SYSTEM
CHINA'S DRUG PRICING REFORMS
FUTURE OF CHINA’S DRUG PRICING REFORMS

CHINA’S OTC DRUG MARKET

FOREIGN ENTRANTS
REGIONAL VARIATIONS
RETAIL MARKET
COSMETICS MARKET

CLINICAL TRIALS MARKET

CLINICAL TRIAL REQUIREMNETS FOR THE LOCAL MARKET
CLINICAL TRIAL REGULATIONS
CLINICAL TRIALS AND CONTRACT RESEARCH ORGANIZATIONS IN CHINA
BENEFITS FOR CHINESE INDUSTRY
BENEFITS FOR FOREIGN PLAYERS
CHALLENGES
RECOMMENDATIONS

PHARMACEUTICAL DISTRIBUTION IN CHINA

STATE CONTROL OF DISTRIBUTION CHANNELS

REGULATORY ISSUES FOR NEW DRUGS IN CHINA

HISTORY OF NEW DRUG REGULATION IN CHINA
CLASSIFICATION OF NEW DRUGS IN CHINA
DRUG REVIEW PROCESS
NEW DRUG REVIEW TIME
NEW DRUG MARKETING EXCLUSIVITY
CLINICAL REQUIREMENTS
IMPORTED DRUGS
CLASS 1 NCE REGISTRATION

INTELLECTUAL PROPERTY PROTECTION ISSUES

INTELLECTUAL PROPERTY PROTECTION IN CHINA
ADMINISTRATIVE PROTECTION
CHANGING IP PROTECTION REGIME
ADAPTATION OF CHINESE FIRMS

TRADITIONAL CHINESE MEDICINE

POPULARITY OF TRADITIONAL CHINESE MEDICINE (TCM) IN CHINA
FORMS OF TCM
TCM DRIVING THE HEALTH FOOD INDUSTRY
POPULARITY OF TCM OUTSIDE OF CHINA
GLOBAL SCOPE FOR CHINESE TCM

FORECASTS FOR THE FUTURE

STRATEGIES FOR THE FUTURE

STRATEGIC OPTIONS FOR CHINESE FIRMS
GENERICS
TRADITIONAL MEDICINE
NCEs
RESEARCH
SUPPORT FOR NEW ENTERPRISES
GOVERNMENT POLICIES

LIST OF TABLES

Table 1: Leading Chinese Provinces By Pharmaceutical Sales
Table 2: Drugs With Largest Market Scope
Table 3: Fastest Growing Therapeutic Categories
Table 4: Registration Procedure For Pharmaceutical Imports
Table 5: Foreign Invested Pharmaceutical Firms
Table 6: Collaboration Between Chinese Firms And Foreign Mncs
Table 7: Government-Set Profit Margins For Drug Types In China
Table 8: Death Rate Of Major Diseases In Urban Areas
Table 9: Death Rate Of Major Diseases In Rural
Table 10: Percentage Of Children Vaccinated For Various Diseases
Table 11: Foreign Insurance Companies In China
Table 12: Leading Pharmaceutical Categories In China’s Retail Market
Table 13: Leading Imported Pharmaceutical Categories In China’s Retail Market
Table 14: Leading Pharmaceutical Manufacturers In China’s Retail Market
Table 15: Leading Pharmaceutical Products In China’s Retail Market By Sales
Table 16: Leading Pharmaceutical Categories In China’s Retail Market By Volume

TABLE OF FIGURES

Figure 1: Size Of Chinese Pharmaceutical & Biotechnology Industry
Figure 2: Break-Up Of Chinese Pharmaceutical Firms Based On Ownership Structure
Figure 3: Break-Up Of Chinese Pharmaceutical Firms Based On Output
Figure 4: Break-Up Of Chinese Pharmaceutical Firms Based On Output
Figure 5: Break-Up Of China’s Drug Market Profile
Figure 6: Projected Break-Up Of China’s Drug Market Profile In 2010
Figure 7: Size Of China’s Pharmaceutical Exports
Figure 8: Chinese Political System
Figure 9: Number Of Biotechnology Companies In China
Figure 10: Sales Of Biotechnology Products In China
Figure 11: Biotechnology Patents Granted In China
Figure 12: Mapping Of The Chinese Government Network In Healthcare
Figure 13: Chinese Healthcare Expenditure
Figure 14: Healthcare Expenditure As A % Of Gnp
Figure 15: Chinese Healthcare Network
Figure 16: Size Of China’s Medical Equipment Market
Figure 17: Insurance Premium Growth In China
Figure 18: Density Of Life Insurance In China
Figure 19: Penetration Of Life Insurance In China
Figure 20: OTC Pharmaceutical Sales In China
Figure 21: Retail Pharmaceutical Outlets In China
Figure 22: China’s Otc Drug Distribution Pattern
Figure 23: China’ Drug Distribution Network